Q-omics provides the consensus-scored TAS2R46 profile across patient tissues and cancer cell-line models. TAS2R46 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TAS2R46 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TAS2R46 RNA expression shows 12,551 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, THCA, and TGCT as cancer lineages where TAS2R46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAS2R46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAS2R46 survival associations across molecular data types. TAS2R46 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAS2R46 RNA expression–survival associations across cancer types. High TAS2R46 expression shows unfavorable associations in KIRC, UVM and KICH, but favorable associations in UCS, SCLC and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .016). Together, the overview and detailed table identify UCS as the clearest survival context for TAS2R46 RNA expression.
This table summarizes TAS2R46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TAS2R46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAS2R46 shows lower tumor expression in THCA and LUAD and higher tumor expression in LUSC, HNSC, ESCA and CHOL. The THCA box plot shows higher TAS2R46 RNA expression in normal versus tumor tissue (log2 FC = −0.154, t-test p < 0.001).
This table shows molecular features associated with TAS2R46 in patient tissues and cancer cell lines. In patient samples, TAS2R46 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TAS2R46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
